The purpose of this study is to test any good and bad effects of the study drug
131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer
from getting worse, but it could also cause side effects. Researchers hope to learn more
about how 131I-omburtamab works in the body, and how effective it is in treating cancer.
131I-Omburtamab is not approved by the FDA to treat DSRCT or other cancers of the peritoneum.
Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.